<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang xml:lang>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Your Digest for Tuesday, Aug 22, 2023 06:59 PM</title>
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    span.underline{text-decoration: underline;}
    div.column{display: inline-block; vertical-align: top; width: 50%;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
  </style>
  <style type="text/css">
:root,
::backdrop {

--sans-font: -apple-system, BlinkMacSystemFont, "Avenir Next", Avenir,
"Nimbus Sans L", Roboto, "Noto Sans", "Segoe UI", Arial, Helvetica,
"Helvetica Neue", sans-serif;
--mono-font: Consolas, Menlo, Monaco, "Andale Mono", "Ubuntu Mono", monospace;
--standard-border-radius: 5px;

--bg: #fff;
--accent-bg: #f5f7ff;
--text: #212121;
--text-light: #585858;
--border: #898EA4;
--accent: #0d47a1;
--code: #d81b60;
--preformatted: #444;
--marked: #ffdd33;
--disabled: #efefef;
}

@media (prefers-color-scheme: dark) {
:root,
::backdrop {
color-scheme: dark;
--bg: #212121;
--accent-bg: #2b2b2b;
--text: #dcdcdc;
--text-light: #ababab;
--accent: #ffb300;
--code: #f06292;
--preformatted: #ccc;
--disabled: #111;
}

img,
video {
opacity: 0.8;
}
}

*, *::before, *::after {
box-sizing: border-box;
}

textarea,
select,
input,
progress {
appearance: none;
-webkit-appearance: none;
-moz-appearance: none;
}
html {

font-family: var(--sans-font);
scroll-behavior: smooth;
}

body {
color: var(--text);
background-color: var(--bg);
font-size: 1.15rem;
line-height: 1.5;
display: grid;
grid-template-columns: 1fr min(45rem, 90%) 1fr;
margin: 0;
}
body > * {
grid-column: 2;
}

body > header {
background-color: var(--accent-bg);
border-bottom: 1px solid var(--border);
text-align: center;
padding: 0 0.5rem 2rem 0.5rem;
grid-column: 1 / -1;
}
body > header h1 {
max-width: 1200px;
margin: 1rem auto;
}
body > header p {
max-width: 40rem;
margin: 1rem auto;
}

main {
padding-top: 1.5rem;
}
body > footer {
margin-top: 4rem;
padding: 2rem 1rem 1.5rem 1rem;
color: var(--text-light);
font-size: 0.9rem;
text-align: center;
border-top: 1px solid var(--border);
}

h1 {
font-size: 3rem;
}
h2 {
font-size: 2.6rem;
margin-top: 3rem;
}
h3 {
font-size: 2rem;
margin-top: 3rem;
}
h4 {
font-size: 1.44rem;
}
h5 {
font-size: 1.15rem;
}
h6 {
font-size: 0.96rem;
}

p, h1, h2, h3, h4, h5, h6 {
overflow-wrap: break-word;
}

h1,
h2,
h3 {
line-height: 1.1;
}

@media only screen and (max-width: 720px) {
h1 {
font-size: 2.5rem;
}
h2 {
font-size: 2.1rem;
}
h3 {
font-size: 1.75rem;
}
h4 {
font-size: 1.25rem;
}
}

a,
a:visited {
color: var(--accent);
}
a:hover {
text-decoration: none;
}
button,
.button,
a.button, 
input[type="submit"],
input[type="reset"],
input[type="button"],
label[type="button"] {
border: none;
border-radius: var(--standard-border-radius);
background-color: var(--accent);
font-size: 1rem;
color: var(--bg);
padding: 0.7rem 0.9rem;
margin: 0.5rem 0;
text-decoration: none;
font-family: inherit;
line-height: normal;
}
.button[aria-disabled="true"], input:disabled,
textarea:disabled,
select:disabled,
button[disabled] {
cursor: not-allowed;
background-color: var(--disabled);
color: var(--text-light)
}
input[type="range"] {
padding: 0;
}

abbr[title] {
cursor: help;
text-decoration-line: underline;
text-decoration-style: dotted;
}
button:enabled:hover,
.button:not([aria-disabled="true"]):hover,
input[type="submit"]:enabled:hover,
input[type="reset"]:enabled:hover,
input[type="button"]:enabled:hover,
label[type="button"]:hover {
filter: brightness(1.4);
cursor: pointer;
}
.button:focus-visible,
button:focus-visible:where(:enabled),
input:enabled:focus-visible:where(
[type="submit"],
[type="reset"],
[type="button"]
) {
outline: 2px solid var(--accent);
outline-offset: 1px;
}

header > nav {
font-size: 1rem;
line-height: 2;
padding: 1rem 0 0 0;
}

header > nav ul,
header > nav ol {
align-content: space-around;
align-items: center;
display: flex;
flex-direction: row;
flex-wrap: wrap;
justify-content: center;
list-style-type: none;
margin: 0;
padding: 0;
}

header > nav ul li,
header > nav ol li {
display: inline-block;
}
header > nav a,
header > nav a:visited {
margin: 0 0.5rem 1rem 0.5rem;
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
color: var(--text);
display: inline-block;
padding: 0.1rem 1rem;
text-decoration: none;
}
header > nav a:hover,
header > nav a.current,
header > nav a[aria-current="page"] {
border-color: var(--accent);
color: var(--accent);
cursor: pointer;
}

@media only screen and (max-width: 720px) {
header > nav a {
border: none;
padding: 0;
text-decoration: underline;
line-height: 1;
}
}

aside, details, pre, progress {
background-color: var(--accent-bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
aside {
font-size: 1rem;
width: 30%;
padding: 0 15px;
margin-inline-start: 15px;
float: right;
}
*[dir="rtl"] aside {
float: left;
}

@media only screen and (max-width: 720px) {
aside {
width: 100%;
float: none;
margin-inline-start: 0;
}
}
article, fieldset, dialog {
border: 1px solid var(--border);
padding: 1rem;
border-radius: var(--standard-border-radius);
margin-bottom: 1rem;
}
article h2:first-child,
section h2:first-child {
margin-top: 1rem;
}
section {
border-top: 1px solid var(--border);
border-bottom: 1px solid var(--border);
padding: 2rem 1rem;
margin: 3rem 0;
}

section + section,
section:first-child {
border-top: 0;
padding-top: 0;
}
section:last-child {
border-bottom: 0;
padding-bottom: 0;
}
details {
padding: 0.7rem 1rem;
}
summary {
cursor: pointer;
font-weight: bold;
padding: 0.7rem 1rem;
margin: -0.7rem -1rem;
word-break: break-all;
}
details[open] > summary + * {
margin-top: 0;
}
details[open] > summary {
margin-bottom: 0.5rem;
}
details[open] > :last-child {
margin-bottom: 0;
}

table {
border-collapse: collapse;
margin: 1.5rem 0;
}
td,
th {
border: 1px solid var(--border);
text-align: start;
padding: 0.5rem;
}
th {
background-color: var(--accent-bg);
font-weight: bold;
}
tr:nth-child(even) {

background-color: var(--accent-bg);
}
table caption {
font-weight: bold;
margin-bottom: 0.5rem;
}

textarea,
select,
input {
font-size: inherit;
font-family: inherit;
padding: 0.5rem;
margin-bottom: 0.5rem;
color: var(--text);
background-color: var(--bg);
border: 1px solid var(--border);
border-radius: var(--standard-border-radius);
box-shadow: none;
max-width: 100%;
display: inline-block;
}
label {
display: block;
}
textarea:not([cols]) {
width: 100%;
}

select:not([multiple]) {
background-image: linear-gradient(45deg, transparent 49%, var(--text) 51%),
linear-gradient(135deg, var(--text) 51%, transparent 49%);
background-position: calc(100% - 15px), calc(100% - 10px);
background-size: 5px 5px, 5px 5px;
background-repeat: no-repeat;
padding-inline-end: 25px;
}
*[dir="rtl"] select:not([multiple]) {
background-position: 10px, 15px;
}

input[type="checkbox"],
input[type="radio"] {
vertical-align: middle;
position: relative;
width: min-content;
}
input[type="checkbox"] + label,
input[type="radio"] + label {
display: inline-block;
}
input[type="radio"] {
border-radius: 100%;
}
input[type="checkbox"]:checked,
input[type="radio"]:checked {
background-color: var(--accent);
}
input[type="checkbox"]:checked::after {

content: " ";
width: 0.18em;
height: 0.32em;
border-radius: 0;
position: absolute;
top: 0.05em;
left: 0.17em;
background-color: transparent;
border-right: solid var(--bg) 0.08em;
border-bottom: solid var(--bg) 0.08em;
font-size: 1.8em;
transform: rotate(45deg);
}
input[type="radio"]:checked::after {

content: " ";
width: 0.25em;
height: 0.25em;
border-radius: 100%;
position: absolute;
top: 0.125em;
background-color: var(--bg);
left: 0.125em;
font-size: 32px;
}

@media only screen and (max-width: 720px) {
textarea,
select,
input {
width: 100%;
}
}

input[type="color"] {
height: 2.5rem;
padding: 0.2rem;
}

input[type="file"] {
border: 0;
}

hr {
border: none;
height: 1px;
background: var(--border);
margin: 1rem auto;
}
mark {
padding: 2px 5px;
border-radius: var(--standard-border-radius);
background-color: var(--marked);
color: black;
}
img,
video {
max-width: 100%;
height: auto;
border-radius: var(--standard-border-radius);
}
figure {
margin: 0;
display: block;
overflow-x: auto;
}
figcaption {
text-align: center;
font-size: 0.9rem;
color: var(--text-light);
margin-bottom: 1rem;
}
blockquote {
margin-inline-start: 2rem;
margin-inline-end: 0;
margin-block: 2rem;
padding: 0.4rem 0.8rem;
border-inline-start: 0.35rem solid var(--accent);
color: var(--text-light);
font-style: italic;
}
cite {
font-size: 0.9rem;
color: var(--text-light);
font-style: normal;
}
dt {
color: var(--text-light);
}

code,
pre,
pre span,
kbd,
samp {
font-family: var(--mono-font);
color: var(--code);
}
kbd {
color: var(--preformatted);
border: 1px solid var(--preformatted);
border-bottom: 3px solid var(--preformatted);
border-radius: var(--standard-border-radius);
padding: 0.1rem 0.4rem;
}
pre {
padding: 1rem 1.4rem;
max-width: 100%;
overflow: auto;
color: var(--preformatted);
}

pre code {
color: var(--preformatted);
background: none;
margin: 0;
padding: 0;
}



progress {
width: 100%;
}
progress:indeterminate {
background-color: var(--accent-bg);
}
progress::-webkit-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent-bg);
}
progress::-webkit-progress-value {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
}
progress::-moz-progress-bar {
border-radius: var(--standard-border-radius);
background-color: var(--accent);
transition-property: width;
transition-duration: 0.3s;
}
progress:indeterminate::-moz-progress-bar {
background-color: var(--accent-bg);
}
dialog {
max-width: 40rem;
margin: auto;
}
dialog::backdrop {
background-color: var(--bg);
opacity: 0.8;
}
@media only screen and (max-width: 720px) {
dialog {
max-width: 100%;
margin: auto 1em;
}
}

.notice {
background: var(--accent-bg);
border: 2px solid var(--border);
border-radius: 5px;
padding: 1.5rem;
margin: 2rem 0;
}

strong{
color:#d81b60;
}
em {
color:#e0467e; 
}
hr
{
border: 1px;
clear: both;
display: block;
width: 100%;
height: 1px;

background-color:#686868
}
</style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">Your Digest for Tuesday, Aug 22, 2023 06:59 PM</h1>
</header>
<hr />
<p>The heart can&#39;t pump enough blood.</p>
<hr />
<h1 id="bcr-abl-is-the-mutation-seen-in-chronic-myeloid-leukemia">BCR-ABL is the mutation seen in chronic myeloid leukemia.</h1>
<p>c-Myc mutations are associated with Burkitt lymphoma.<br />
P53 mutations are associated with many cancers.</p>
<hr />
<p><strong>Definition:</strong> In terms of haemodynamics, the heart cannot pump enough blood to meet the needs of the body or can do so only under <em>high filling pressures</em>.</p>
<h1 id="heart-failure-with-preserved-ejection-fraction">Heart failure with preserved ejection fraction.</h1>
<p>==Is HFpEF the same thing as &#39;diastolic failure&#39;?==</p>
<p>Diastolic dysfunction = abnormal cardiac relaxtion = stiffness = abnormal filling.<br />
Usually, systolic and diastolic dysfunction occur simultaneously.</p>
<p>HFpEF characteristically has</p>
<ol>
<li><strong>normal LV ejection fraction</strong>.</li>
<li>Normal left ventricular end diastolic volume</li>
<li><strong>abnormal diastolic function</strong> usually with LV concentric remodeling or hypertrophy.</li>
</ol>
<p><em>There is technically a difference between diastolic dysfunction and HFpEF</em>:</p>
<ol>
<li>Impaired relaxation / stiffness / abnormal filling can occur without symptoms of heart failure =&gt; &#39;diastolic dysfunction&#39;.</li>
<li>Diastolic dysfunction <strong>+ clinical features of heart failure</strong> =&gt; <strong>HFpEF</strong>.</li>
</ol>
<p>HFrEF = EF &lt; 40%;<br />
HRpEF = EF &gt; 50%;</p>
<p>==If so, what causes HFpEF? Are the the same things that cause ventricular hypertrophy?==</p>
<ul>
<li>the leading risk factors for HFpEF are older age, systemic hypertension, obesity, sedentary lifestyle, and myocardial ischemia.</li>
</ul>
<p>==Which ventricle fails in HFpEF?==<br />
Chronic HF is divided into HFrEF and HFpEF based on <strong>left ventricular</strong> ejection fraction.<br />
Pulmonary hypertension is a known complication of HFpEF and presumably, can <em>lead to</em> RV failure.</p>
<p>==How are the symptoms of HFpEF different from HFrEF?==</p>
<blockquote>
<p>The clinical manifestations of HFpEF are generally the same as those for other forms of HF</p>
</blockquote>
<table>
<thead>
<tr class="header">
<th>Symptoms and signs of heart failure</th>
<th>Percentage of patients (%)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>DOE</td>
<td>98</td>
</tr>
<tr class="even">
<td>Fatigue</td>
<td>59</td>
</tr>
<tr class="odd">
<td>Edema</td>
<td>45</td>
</tr>
<tr class="even">
<td>Orthopnea</td>
<td>22</td>
</tr>
<tr class="odd">
<td>JVD</td>
<td>17</td>
</tr>
<tr class="even">
<td>Rales</td>
<td>11</td>
</tr>
<tr class="odd">
<td>PND</td>
<td>7.60</td>
</tr>
<tr class="even">
<td>Dyspnea at rest</td>
<td>4.60</td>
</tr>
</tbody>
</table>
<p><strong>Stages</strong> of heart failure (define by the AHA)</p>
<table>
<thead>
<tr class="header">
<th>Stage</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Stage A: At risk for heart failure</td>
<td>People who are at risk for heart failure but do not yet have symptoms or structural or functional heart disease Risk factors for people in this stage include hypertension, coronary vascular disease, diabetes, obesity, exposure to cardiotoxic agents, genetic variants for cardiomyopathy and family history of cardiomyopathy</td>
</tr>
<tr class="even">
<td>Stage B: Pre-heart failure</td>
<td>People without current or previous symptoms of heart failure but with either structural heart disease, increased filling pressures in the heart or other risk factors</td>
</tr>
<tr class="odd">
<td>Stage C: Symptomatic heart failure</td>
<td>People with current or previous symptoms of heart failure</td>
</tr>
<tr class="even">
<td>Stage D: Advanced heart failure</td>
<td>People with heart failure symptoms that interfere with daily life functions or lead to repeated hospitalizations</td>
</tr>
</tbody>
</table>
<p><strong>NYHA</strong> classes of heart failure</p>
<table>
<thead>
<tr class="header">
<th>Class</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>I</td>
<td><strong>No limitation</strong> of physical activity. Ordinary physical activity <em>does not cause undue fatigue</em>, palpitation or shortness of breath.</td>
</tr>
<tr class="even">
<td>II</td>
<td><strong>Slight limitation</strong> of physical activity. Comfortable at rest. <em>Ordinary physical</em> activity results in fatigue, palpitation, shortness of breath or chest pain.</td>
</tr>
<tr class="odd">
<td>III</td>
<td><strong>Marked limitation</strong> of physical activity. Comfortable at rest. <em>Less than ordinary</em> activity causes fatigue, palpitation, shortness of breath or chest pain.</td>
</tr>
<tr class="even">
<td>IV</td>
<td><strong>Symptoms of heart failure at rest</strong>. <em>Any physical activity</em> causes further discomfort.</td>
</tr>
</tbody>
</table>
<p>==What are the options for management of HFpEF?==</p>
<h2 id="pharmacotherapy-of-heart-failure-with-preserved-ejection-fraction">Pharmacotherapy of heart failure with preserved ejection fraction</h2>
<p>Goals of treatment:</p>
<ol>
<li>reduce symptoms</li>
<li>reduce hospital admission</li>
<li>improve functional status.</li>
</ol>
<p><strong>Preferred pharmacotherapies:</strong></p>
<ul>
<li><p>loop diuretics for initial therapy</p></li>
<li><p><strong>sodium-glucose co-transporter 2 (SGLT2) inhibitor</strong></p></li>
<li><p>a <strong>mineralocorticoid receptor antagonist</strong> (MRA) (eg Spironolactone)</p></li>
<li><p>SGLT2 inhibitors and MRAs reduce the risk of hospitalization.</p></li>
<li><p>The following agents <strong>are not routinely used</strong> because they have not been proven to have benefits in HFpEF!</p>
<ul>
<li>ARNI - sacubitril-valsartan,</li>
<li>angiotensin II receptor blockers [ARBs] (eg. Losartan),</li>
<li>angiotensin converting enzyme [ACE] inhibitors,</li>
<li>calcium channel blockers [CCBs]</li>
<li>Beta blockers</li>
<li></li>
</ul></li>
</ul>
</body>
</html>
